Wednesday, January 10, 2024

#Pulmonary #Fibrosis and #COPD #Serracor



Serracor-NK 150/ 300 Vegetarian Caps Circulatory & Respiratory Support Systemic Enzyme Formula  Contains Enteric-Coated Serrapeptase & Nattokinase 

I read your recent column on pulmonary fibrosis. I especially appreciate knowing that there are medications known to slow progression of lung disease, reduce exacerbation and reduce mortality. With a 20-year-old diagnosis of COPD and having been prescribed medications to reduce exacerbations, you might imagine my interest in your article.

I’m wondering how pulmonary fibrosis differs from COPD and if the two medications that you mention (pirfenidone and nintedanib) might be helpful in slowing the progression of lung disease in patients such as myself. Have any studies been completed using these medications on patients with COPD?

DEAR READER >> Chronic obstructive pulmonary disease — its two main forms are emphysema and chronic bronchitis — usually, but not invariably, is a result of long-term exposure to lung toxins, especially smoke. In the most common case of COPD, due to cigarette smoking (at least, that’s the most common in North America and Europe: cooking fires are still a common cause in less developed countries), stopping the exposure will dramatically slow down further damage. Unfortunately, there are no established treatments that can restore lung function in people with moderate to advanced COPD.

Pulmonary fibrosis is, by contrast, a rare disease; about 30,000 people in the U.S. are diagnosed each year (compare that with the 9 million people in the U.S. diagnosed with chronic bronchitis last year).

The exact mechanism of action of pirfenidone and nintedanib is not known, but they are not thought to be effective in COPD. Surprisingly, I did not find a published trial looking at whether these drugs might be effective. The need for new therapies to treat COPD is so great that I would have thought some researcher might have tried it, despite the long odds.

The benefits of nattokinase and serrapeptase in the treatment of many major lung issues, like COPD is just remarkable. Both enzymes are shown to have a major impact on inflammation. Both nattokinase and serrapeptase are fibrinolytic enzymes. The blood thinning and oxygenating properties of nattokinase make it an appropriate remedy for COPD, Empsyemia and Pulmonary Fibrosis.  Symptoms matchup

Click the Buy NOW save 10% 
regular price $124 
Direct $112.49 price with free shipping